Zentalis Pharmaceuticals’ $250 Million Underwritten Offering of Common Stock

Latham & Watkins represented Zentalis in the offering, and Cooley represented the underwriters.Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL) announced the pricing of an underwritten offering of 11,032,656…

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here
Avatar

Author: Pietro Martinoia

Standard 1 Year Membership Required

You must be a Standard 1 Year member to access this content.

Join Now

Already a member? Log in here